Deciphering the localization and trajectory of human natural killer cell development
- PMID: 36869821
- DOI: 10.1093/jleuko/qiad027
Deciphering the localization and trajectory of human natural killer cell development
Abstract
Innate immune cells represent the first line of cellular immunity, comprised of both circulating and tissue-resident natural killer cells and innate lymphoid cells. These innate lymphocytes arise from a common CD34+ progenitor that differentiates into mature natural killer cells and innate lymphoid cells. The successive stages in natural killer cell maturation are characterized by increased lineage restriction and changes to phenotype and function. Mechanisms of human natural killer cell development have not been fully elucidated, especially the role of signals that drive the spatial localization and maturation of natural killer cells. Cytokines, extracellular matrix components, and chemokines provide maturation signals and influence the trafficking of natural killer cell progenitors to peripheral sites of differentiation. Here we present the latest advances in our understanding of natural killer and innate lymphoid cell development in peripheral sites, including secondary lymphoid tissues (i.e. tonsil). Recent work in the field has provided a model for the spatial distribution of natural killer cell and innate lymphoid cell developmental intermediates in tissue and generated further insights into the developmental niche. In support of this model, future studies using multifaceted approaches seek to fully map the developmental trajectory of human natural killer cells and innate lymphoid cells in secondary lymphoid tissues.
Keywords: chemokines; cytokines; hematopoietic stem cells; innate immunity; innate lymphoid progenitors; secondary lymphoid tissue.
© The Author(s) 2023. Published by Oxford University Press on behalf of Society for Leukocyte Biology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Conflict of interest statement
Conflict of interest statement. None declared.
Similar articles
-
Evidence for discrete stages of human natural killer cell differentiation in vivo.J Exp Med. 2006 Apr 17;203(4):1033-43. doi: 10.1084/jem.20052507. Epub 2006 Apr 10. J Exp Med. 2006. PMID: 16606675 Free PMC article.
-
A Progenitor Cell Expressing Transcription Factor RORγt Generates All Human Innate Lymphoid Cell Subsets.Immunity. 2016 May 17;44(5):1140-50. doi: 10.1016/j.immuni.2016.04.007. Epub 2016 May 10. Immunity. 2016. PMID: 27178467 Free PMC article.
-
Human natural killer cell development in secondary lymphoid tissues.Semin Immunol. 2014 Apr;26(2):132-7. doi: 10.1016/j.smim.2014.02.008. Epub 2014 Mar 21. Semin Immunol. 2014. PMID: 24661538 Free PMC article. Review.
-
CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway.Immunity. 2018 Sep 18;49(3):464-476.e4. doi: 10.1016/j.immuni.2018.08.010. Epub 2018 Sep 4. Immunity. 2018. PMID: 30193847 Free PMC article.
-
Overview of the development, characterization, and function of human types 1, 2, and 3 innate lymphoid cells.Einstein (Sao Paulo). 2024 Nov 29;22:eRW1042. doi: 10.31744/einstein_journal/2024RW1042. eCollection 2024. Einstein (Sao Paulo). 2024. PMID: 39630753 Free PMC article. Review.
Cited by
-
Metabolic programs drive function of therapeutic NK cells in hypoxic tumor environments.Sci Adv. 2024 Nov;10(44):eadn1849. doi: 10.1126/sciadv.adn1849. Epub 2024 Oct 30. Sci Adv. 2024. PMID: 39475618 Free PMC article.
-
A temporal developmental map separates human NK cells from noncytotoxic ILCs through clonal and single-cell analysis.Blood Adv. 2024 Jun 11;8(11):2933-2951. doi: 10.1182/bloodadvances.2023011909. Blood Adv. 2024. PMID: 38484189 Free PMC article.
-
Cancer immunity by tissue-resident type 1 innate lymphoid cells and killer innate-like T cells.Immunol Rev. 2024 May;323(1):150-163. doi: 10.1111/imr.13319. Epub 2024 Mar 20. Immunol Rev. 2024. PMID: 38506480 Free PMC article. Review.
-
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances.Exp Hematol Oncol. 2024 Dec 4;13(1):118. doi: 10.1186/s40164-024-00583-7. Exp Hematol Oncol. 2024. PMID: 39633491 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources